| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/OXFORDJOURNALS.AJE.A113861 |
| P698 | PubMed publication ID | 6377880 |
| P2093 | author name string | Kwon-Chung KJ | |
| Bennett JE | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cryptococcus neoformans | Q131924 |
| epidemiology | Q133805 | ||
| P304 | page(s) | 123-130 | |
| P577 | publication date | 1984-07-01 | |
| P1433 | published in | American Journal of Epidemiology | Q4744243 |
| P1476 | title | Epidemiologic differences between the two varieties of Cryptococcus neoformans | |
| P478 | volume | 120 |
| Q33692330 | 'Popping the clutch': novel mechanisms regulating sexual development in Cryptococcus neoformans |
| Q50149203 | A Call to Arms: Quest for a Cryptococcal Vaccine. |
| Q39443145 | A case of primary cutaneous cryptococcosis |
| Q30406964 | A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients |
| Q35953210 | A murine model of Cryptococcus gattii meningoencephalitis |
| Q30495712 | A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease |
| Q24558831 | A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada) |
| Q54568764 | A retrotransposon-derived probe for discriminating strains of Cryptococcus neoformans. |
| Q43230278 | AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid |
| Q45788009 | Analysis of leucocytes and lymphocyte subsets in cats with naturally‐occurring cryptococcosis but differing feline immunodeficiency virus status |
| Q35386000 | Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages |
| Q42111821 | Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans |
| Q39464117 | Are two Cryptococcus neoformans strains epidemiologically linked? |
| Q36095320 | Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens |
| Q41968268 | Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin |
| Q43796047 | Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. |
| Q33560210 | Cas3p belongs to a seven-member family of capsule structure designer proteins |
| Q48251141 | Cerebral cryptococcoma mimicking glioblastoma |
| Q37655143 | Chapter 3--pulmonary cryptococcosis |
| Q37007244 | Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. |
| Q35689915 | Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States |
| Q69566685 | Clinical and environmental isolates of Cryptococcus neoformans in Bangkok (Thailand) |
| Q35040931 | Clinical characteristics and predictors of mortality for Cryptococcus gattii infection in dogs and cats of southwestern British Columbia. |
| Q57610659 | Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan |
| Q39502220 | Clinical isolates of Cryptococcus neoformans from Zaire |
| Q33839536 | Clonality and α-a recombination in the Australian Cryptococcus gattii VGII population--an emerging outbreak in Australia |
| Q49287757 | Colliding Epidemics and the Rise of Cryptococcosis. |
| Q34097624 | Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. |
| Q36523409 | Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformans. The Cryplococcal Disease Active Surveillance Group |
| Q36532829 | Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. |
| Q42924504 | Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States |
| Q41903839 | CrAg lateral flow assay for cryptococcosis |
| Q40494968 | Cryptococcal cellulitis in a heart transplant recipient. |
| Q37026055 | Cryptococcal infections in non-HIV-infected patients |
| Q38098090 | Cryptococcal infections: changing epidemiology and implications for therapy. |
| Q33633343 | Cryptococcal meningitis: epidemiology and therapeutic options |
| Q78746513 | Cryptococcosis |
| Q35507498 | Cryptococcosis in AIDS. |
| Q35532573 | Cryptococcosis in HIV negative patients: findings on chest radiography |
| Q30424017 | Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. |
| Q38155197 | Cryptococcus antigens and immune responses: implications for a vaccine |
| Q84769107 | Cryptococcus gattii VGI in a Spinner Dolphin (Stenella longirostris) from Hawaii |
| Q21131358 | Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal |
| Q37969662 | Cryptococcus gattii comparative genomics and transcriptomics: a NIH/NIAID White Paper |
| Q37302544 | Cryptococcus gattii dispersal mechanisms, British Columbia, Canada |
| Q31138137 | Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates |
| Q43513052 | Cryptococcus gattii infection in an immunocompetent patient from Southern Italy |
| Q27002687 | Cryptococcus gattii infections |
| Q37261982 | Cryptococcus gattii infections in multiple states outside the US Pacific Northwest |
| Q38165199 | Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. |
| Q33636108 | Cryptococcus gattii outbreak expands into the Northwestern United States with fatal consequences |
| Q43428999 | Cryptococcus gattii serotype-C strains isolated in Bangalore, Karnataka, India |
| Q33797765 | Cryptococcus gattii virulence composite: candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains |
| Q37201768 | Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America |
| Q37111315 | Cryptococcus gattii: Emergence in Western North America: Exploitation of a Novel Ecological Niche. |
| Q35489889 | Cryptococcus gattii: a resurgent fungal pathogen |
| Q30403990 | Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals |
| Q33790656 | Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis |
| Q43938878 | Cryptococcus neoformans isolated from patients with AIDS |
| Q36988205 | Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity |
| Q37009217 | Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China |
| Q69865076 | Cryptococcus neoformans var gattii in Europe |
| Q39197021 | Cryptococcus neoformans var. gattii among patients with cryptococcal meningitis in Mexico. First observations |
| Q40189555 | Cryptococcus neoformans var. gattii in Australia. |
| Q43935677 | Cryptococcus neoformans var. gattii in a Brazilian AIDS patients |
| Q39466229 | Cryptococcus neoformans var. neoformans (serotype D) strains are more susceptible to heat than C. neoformans var. grubii (serotype A) strains |
| Q39232074 | Cryptococcus neoformans varieties as agents of cryptococcosis in Brazil |
| Q39372320 | Cryptococcus neoformans, Cryptococcus gattii: serotypes in Venezuela |
| Q70142899 | Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC |
| Q38229538 | Current concepts in cryptococcosis |
| Q28080670 | Current trends in the prevalence of Cryptococcus gattii in the United States and Canada |
| Q35806918 | Cyclic AMP-dependent protein kinase catalytic subunits have divergent roles in virulence factor production in two varieties of the fungal pathogen Cryptococcus neoformans |
| Q37250043 | DNA probe for strain typing of Cryptococcus neoformans |
| Q36547129 | DNA typing suggests pigeon droppings as a source of pathogenic Cryptococcus neoformans serotype D. |
| Q58798947 | Dectin-3 Recognizes Glucuronoxylomannan of Serotype AD and Serotype B to Initiate Host Defense Against Cryptococcosis |
| Q33677651 | Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies |
| Q28481671 | Differences in nitrogen metabolism between Cryptococcus neoformans and C. gattii, the two etiologic agents of cryptococcosis |
| Q37862620 | Disseminated Histoplasma capsulatum and Cryptococcus neoformans co-infection in patients with AIDS. |
| Q70408416 | Disseminated cryptococcosis due to Cryptococcus neoformans variety gattii in a Canadian patient with AIDS |
| Q36523262 | Diversity of DNA fingerprints in Cryptococcus neoformans |
| Q33837837 | Ecological niche modeling of Cryptococcus gattii in British Columbia, Canada |
| Q35423201 | Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion |
| Q33565424 | Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States |
| Q34418533 | Emerging and reemerging neurologic infections |
| Q33900556 | Endogenous endophthalmitis caused by Cryptococcus neoformans Var. Gattii mimicking choroidal tumor: From positron-emission tomography/computed tomography to histopathology |
| Q44547156 | Environmental distribution of Cryptococcus neoformans in the department of Cundinamarca-Colombia |
| Q33962933 | Epidemiological evidence for dormant Cryptococcus neoformans infection |
| Q41991790 | Epidemiology and trends of cryptococcosis in the United States from 2000 to 2007: A population-based study |
| Q34216198 | Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. |
| Q37247919 | Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies |
| Q42582627 | Evidence of mRNA-mediated intron loss in the human-pathogenic fungus Cryptococcus neoformans |
| Q54978161 | Evolutionarily Conserved and Divergent Roles of Unfolded Protein Response (UPR) in the Pathogenic Cryptococcus Species Complex. |
| Q50988167 | Exposure to Cryptococcus neoformans var. gattii--a seroepidemiological study. |
| Q36022995 | Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population |
| Q33885239 | First case of human cryptococcosis due to Cryptococcus neoformans var. gattii in Spain |
| Q37825451 | First environmental isolations of Cryptococcus neoformans and Cryptococcus gattii in Tunisia and review of published studies on environmental isolations in Africa |
| Q38895473 | First identification of autochthonous Cryptococcus neoformans var. gattii isloated from goats with predominantly severe pulmonary disease in Spain. |
| Q33466017 | First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen |
| Q46689795 | Fitness distribution and transgressive segregation across 40 environments in a hybrid progeny population of the human-pathogenic yeast Cryptococcus neoformans |
| Q31121171 | Forecasted Impact of Climate Change on Infectious Disease and Health Security in Hawaii by 2050. |
| Q35137799 | Fungal diagnostics |
| Q43077769 | Fungal serotype-specific differences in bacterial-yeast interactions |
| Q33466055 | Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. |
| Q40013259 | Genetic relatedness and diversity of Cryptococcus neoformans strains in the Maltese Islands. |
| Q34565901 | Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. |
| Q41229705 | Glucosamine stimulates pheromone-independent dimorphic transition in Cryptococcus neoformans by promoting Crz1 nuclear translocation |
| Q40037118 | Growth and mating of Cryptococcus neoformans var. grubii on woody debris |
| Q38223670 | Host-parasite interaction in fungal infections |
| Q37132904 | Hybridization probes for conventional DNA fingerprinting used as single primers in the polymerase chain reaction to distinguish strains of Cryptococcus neoformans |
| Q36168992 | Identification and Characterization of VNI/VNII and Novel VNII/VNIV Hybrids and Impact of Hybridization on Virulence and Antifungal Susceptibility Within the C. neoformans/C. gattii Species Complex |
| Q50266233 | Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII. |
| Q30224617 | Implications of climate change (global warming) for the healthcare system |
| Q33696932 | In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates |
| Q37575561 | In vitro antifungal susceptibility of Cryptococcus gattii |
| Q47118458 | Induction of Broad-Spectrum Protective Immunity against Disparate Cryptococcus Serotypes. |
| Q34474486 | Induction of brain microvascular endothelial cell urokinase expression by Cryptococcus neoformans facilitates blood-brain barrier invasion |
| Q39169028 | Infection with Cryptococcus neoformans var. gattii leading to a pulmonary cryptococcoma and meningitis |
| Q37643828 | Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production |
| Q37975991 | Intra-abdominal cryptococcosis by Cryptococcus gattii: case report and review |
| Q111624006 | Intrageneric Effect of Killer Toxin Produced by Cryptococcus Laurentii |
| Q47583983 | Investigation of the basis of virulence in serotype A strains of Cryptococcus neoformans from apparently immunocompetent individuals |
| Q37375089 | Is Cryptococcus gattii a Primary Pathogen? |
| Q41895149 | Isolation and Characterization of Cryptococcus neoformans from Environmental Sources in Busan |
| Q44078226 | Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans |
| Q74457742 | Isolation of Cryptococcus neoformans from pigeon (Columbia livia droppings in northern Iran |
| Q36871096 | Late presentation of Cryptococcus gattii meningitis in a traveller to Vancouver Island: A case report |
| Q34292528 | MALDI-TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex |
| Q39162544 | Meningitis caused by Cryptococcus neoformans var. gattii and var. neoformans in Papua New Guinea. |
| Q46951395 | Meningitis due to Cryptococcus neoformans biovar gattii in a Zairean AIDS patient |
| Q40183788 | Methodology for Anti-Cryptococcal Vaccine Development |
| Q36704709 | Microreview: capsule-associated genes of Cryptococcus neoformans |
| Q40404214 | Molecular analysis of Cryptococcus neoformans mitochondrial cytochrome b gene sequences |
| Q43900771 | Molecular epidemiology of isolates of the Cryptococcus neoformans species complex from Spain |
| Q24632155 | Molecular mechanisms of cryptococcal meningitis |
| Q36530376 | Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group |
| Q37093459 | Molecular typing of Cryptococcus neoformans serotype D clinical isolates. |
| Q35115708 | Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy |
| Q34596637 | Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1. |
| Q33754371 | Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans |
| Q37139073 | Multilocus enzyme typing of Cryptococcus neoformans. |
| Q36532871 | Natural environmental sources of Cryptococcus neoformans var. gattii |
| Q37186662 | Natural habitat of Cryptococcus neoformans var. gattii |
| Q37156556 | New Insights into HIV/AIDS-Associated Cryptococcosis |
| Q73917933 | Novel therapeutic approach by culture filtrate of Cryptococcus neoformans var. gattii (CneF) in experimental immune complex glomerulonephritis |
| Q39751630 | PCR-restriction fragment length polymorphism analysis of the phospholipase B (PLB1) gene for subtyping of Cryptococcus neoformans isolates |
| Q73936271 | Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors |
| Q34543565 | Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat |
| Q36535256 | Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients |
| Q33899747 | Phenotypic differences of Cryptococcus molecular types and their implications for virulence in a Drosophila model of infection |
| Q48070816 | Polymerase chain reaction fingerprinting in fungi using single primers specific to minisatellites and simple repetitive DNA sequences: strain variation in Cryptococcus neoformans |
| Q39457535 | Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City |
| Q34061252 | Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea |
| Q35225603 | Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D. |
| Q33926640 | Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry |
| Q42850204 | Rapid identification of Cryptococcus neoformans var. grubii, C. neoformans var. neoformans, and C. gattii by use of rapid biochemical tests, differential media, and DNA sequencing |
| Q34355333 | Rapid mechanisms for generating genome diversity: whole ploidy shifts, aneuploidy, and loss of heterozygosity |
| Q34190284 | Regulatory circuitry governing fungal development, drug resistance, and disease. |
| Q37084983 | Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City |
| Q34549620 | Retrospective study of the epidemiology and clinical manifestations of Cryptococcus gattii infections in Colombia from 1997-2011. |
| Q35556339 | Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. |
| Q36757799 | Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen |
| Q45253337 | Serotypes and mating types of clinical strains of Cryptococcus neoformans isolated in Taiwan |
| Q50753485 | Serotypes of Cryptococcus neoformans isolated from patients prior to and during the AIDS era in Thailand. |
| Q34747969 | Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns |
| Q36527966 | Serotyping of Cryptococcus neoformans by dot enzyme assay. |
| Q37064239 | Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. |
| Q33974698 | Serotyping of Cryptococcus neoformans isolates from clinical and environmental sources in Spain |
| Q73590226 | Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents |
| Q33768483 | Specialization of the HOG pathway and its impact on differentiation and virulence of Cryptococcus neoformans |
| Q33602561 | Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay. |
| Q30490385 | Spores as infectious propagules of Cryptococcus neoformans |
| Q24652835 | Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA |
| Q67759043 | The Discovery of Creatinine Assimilation in Cryptococcus neoformans, and Subsequent Work on the Characterization of the Two Varieties of C. neoformans |
| Q57466063 | The effects of environmental and genetic factors on the germination of basidiospores in the Cryptococcus gattii species complex |
| Q53125498 | The emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. |
| Q39761162 | The genetics of medically important fungi |
| Q33490038 | The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii |
| Q37274762 | Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding |
| Q35106377 | Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest |
| Q44176269 | Treatment of experimental nephrosis by culture filtrate of Cryptococcus neoformans var. gattii (CneF). |
| Q39826877 | Tumor necrosis factor-inducing activities of Cryptococcus neoformans components |
| Q37125444 | Typing of Histoplasma capsulatum by restriction fragment length polymorphisms in a nuclear gene |
| Q31149511 | Urease activity in Cryptococcus neoformans and Cryptococcus gattii |
| Q37021484 | Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans |
| Q30985945 | Use of a dispersed repetitive DNA element to distinguish clinical isolates of Cryptococcus neoformans |
| Q33221146 | Use of a suspension array for rapid identification of the varieties and genotypes of the Cryptococcus neoformans species complex |
| Q36192774 | Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models |
| Q28541882 | Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice |
| Q35411136 | Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis |
| Q40927145 | Virulence factors of Cryptococcus neoformans |
| Q37402023 | Virulence in Cryptococcus species |
| Q36944807 | Virulence, serotype, and molecular characteristics of environmental strains of Cryptococcus neoformans var. gattii |
| Q46356008 | Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattii meningitis |
Search more.